Tobin Juvenal Sells 3,306 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Posted by Brian Himes on Sep 18th, 2026

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) insider Tobin Juvenal sold 3,306 shares of Castle Biosciences stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $32.32, for a total transaction of $106,849.92. Following the sale, the insider owned 61,878 shares of the company’s stock, valued at approximately $1,999,896.96. The trade was a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Up 3.7%

CSTL stock opened at $36.78 on Friday. The company has a market capitalization of $1.12 billion, a P/E ratio of -55.73 and a beta of 0.99. Castle Biosciences, Inc. has a 12 month low of $17.72 and a 12 month high of $44.28. The firm’s fifty day simple moving average is $30.04 and its 200-day simple moving average is $25.62. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.34. The firm had revenue of $99.86 million during the quarter, compared to analysts’ expectations of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. As a group, equities research analysts forecast that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CSTL. Weiss Ratings upgraded Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Roth Capital assumed coverage on Castle Biosciences in a research note on Wednesday, June 24th. They issued a “buy” rating and a $40.00 target price on the stock. BTIG Research raised their target price on Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. KeyCorp set a $35.00 price target on Castle Biosciences in a research report on Friday, May 29th. Finally, Zacks Research downgraded Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Get Our Latest Report on Castle Biosciences

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Global Retirement Partners LLC acquired a new position in Castle Biosciences in the 2nd quarter worth about $26,000. Quantbot Technologies LP purchased a new position in Castle Biosciences during the second quarter worth approximately $62,000. Caitong International Asset Management Co. Ltd boosted its position in Castle Biosciences by 140.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,750 shares of the company’s stock worth $68,000 after purchasing an additional 1,022 shares in the last quarter. State of Wyoming acquired a new stake in Castle Biosciences in the second quarter valued at approximately $117,000. Finally, Assetmark Inc. grew its holdings in Castle Biosciences by 9.3% in the first quarter. Assetmark Inc. now owns 5,779 shares of the company’s stock valued at $142,000 after purchasing an additional 492 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Castle Biosciences

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians make more informed decisions about cancer diagnosis and treatment. Its products use genomic and molecular information to assess disease characteristics, patient risk and likely outcomes.

The company’s portfolio includes DecisionDx-Melanoma, which helps assess the risk of metastasis in patients with cutaneous melanoma; DecisionDx-SCC, which evaluates metastatic risk in certain patients with cutaneous squamous cell carcinoma; and MyPath Melanoma, which assists in distinguishing benign from malignant melanocytic lesions.